טוען...
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group
2006
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361407/ https://ncbi.nlm.nih.gov/pubmed/16622463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603085 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|